Egetis Therapeutics AB (publ)

LSE:0ABW Stock Report

Market Cap: SEK 2.0b

Egetis Therapeutics Valuation

Is 0ABW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0ABW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0ABW (SEK5.6) is trading below our estimate of fair value (SEK133.36)

Significantly Below Fair Value: 0ABW is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0ABW?

Key metric: As 0ABW is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0ABW. This is calculated by dividing 0ABW's market cap by their current revenue.
What is 0ABW's PS Ratio?
PS Ratio29.6x
SalesSEK 67.90m
Market CapSEK 2.01b

Price to Sales Ratio vs Peers

How does 0ABW's PS Ratio compare to its peers?

The above table shows the PS ratio for 0ABW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.4x
BVXP Bioventix
14.4xn/aUK£195.7m
AVCT Avacta Group
7.8x0.4%UK£175.6m
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
AREC Arecor Therapeutics
5.9x35.2%UK£28.9m
0ABW Egetis Therapeutics
29.6x81.7%SEK 2.0b

Price-To-Sales vs Peers: 0ABW is expensive based on its Price-To-Sales Ratio (29.6x) compared to the peer average (7.4x).

Price to Sales Ratio vs Industry

How does 0ABW's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.6x21.0%US$561.69m
TRX Tissue Regenix Group
1.6x15.1%US$50.93m
VRCI Verici Dx
2.4x78.8%US$10.27m
0ABW 29.6xIndustry Avg. 7.9xNo. of Companies7PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0ABW is expensive based on its Price-To-Sales Ratio (29.6x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0ABW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0ABW PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio29.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0ABW's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0ABW forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 5.60
SEK 10.80
+92.9%
25.8%SEK 14.00SEK 6.00n/a5
Nov ’25n/a
SEK 11.40
0%
26.4%SEK 15.00SEK 6.00n/a5
Oct ’25SEK 4.66
SEK 11.40
+144.6%
26.4%SEK 15.00SEK 6.00n/a5
Sep ’25SEK 5.80
SEK 11.40
+96.6%
26.4%SEK 15.00SEK 6.00n/a5
Aug ’25SEK 5.83
SEK 13.30
+128.1%
32.7%SEK 18.00SEK 6.00n/a5
Jul ’25SEK 4.73
SEK 13.30
+181.5%
32.7%SEK 18.00SEK 6.00n/a5
Jun ’25SEK 8.71
SEK 14.30
+64.2%
20.2%SEK 18.00SEK 11.00n/a5
May ’25SEK 5.94
SEK 13.13
+120.9%
19.5%SEK 17.50SEK 11.00n/a4
Apr ’25SEK 6.69
SEK 13.13
+96.2%
19.5%SEK 17.50SEK 11.00n/a4
Mar ’25SEK 6.61
SEK 13.13
+98.5%
19.5%SEK 17.50SEK 11.00n/a4
Feb ’25SEK 5.79
SEK 12.75
+120.2%
15.1%SEK 16.00SEK 11.00n/a4
Jan ’25SEK 5.52
SEK 11.10
+101.1%
32.0%SEK 16.00SEK 5.00n/a5
Dec ’24SEK 4.77
SEK 11.10
+132.7%
32.0%SEK 16.00SEK 5.00n/a5
Nov ’24SEK 4.99
SEK 11.10
+122.7%
32.0%SEK 16.00SEK 5.00n/a5
Oct ’24SEK 4.49
SEK 11.10
+147.2%
32.0%SEK 16.00SEK 5.00SEK 4.665
Sep ’24n/a
SEK 11.10
0%
32.0%SEK 16.00SEK 5.00SEK 5.805
Aug ’24SEK 4.34
SEK 11.50
+165.3%
36.1%SEK 18.00SEK 5.00SEK 5.835
Jul ’24SEK 4.45
SEK 13.90
+212.4%
18.5%SEK 18.00SEK 10.50SEK 4.735
Jun ’24SEK 4.95
SEK 14.50
+193.2%
14.5%SEK 18.00SEK 11.50SEK 8.715
May ’24SEK 8.55
SEK 16.50
+93.0%
26.0%SEK 24.00SEK 11.50SEK 5.945
Apr ’24SEK 7.80
SEK 16.50
+111.5%
26.0%SEK 24.00SEK 11.50SEK 6.695
Mar ’24SEK 5.22
SEK 14.63
+180.2%
15.9%SEK 18.00SEK 11.50SEK 6.614
Feb ’24SEK 6.11
SEK 15.67
+156.4%
10.8%SEK 18.00SEK 14.00SEK 5.793
Jan ’24n/a
SEK 17.75
0%
22.0%SEK 24.00SEK 14.00SEK 5.524
Dec ’23n/a
SEK 15.67
0%
39.8%SEK 24.00SEK 9.00SEK 4.773
Nov ’23n/a
SEK 16.50
0%
45.5%SEK 24.00SEK 9.00SEK 4.992

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.80

7D

1.9%

1Y

12.1%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

7D

0.5%

1Y

-5.7%